About Us

Dr. David M. Reese is Amgen’s inaugural executive vice president and chief technology officer, overseeing technology and artificial intelligence across the company. He joined Amgen in 2005 and previously served as executive vice president of Research and Development. Prior to Amgen, Dr. Reese was director of Clinical Research for the Breast Cancer International Research Group and a co-founder of Translational Oncology Research International. He is a graduate of Harvard College and the University of Cincinnati College of Medicine.

Dr. James H. Goodnight is the co-founder, president, and CEO of SAS, an analytics software company based in Cary, NC. He has led the company since its inception in 1976, overseeing a continuous chain of revenue growth and profitability. Dr. Goodnight earned his bachelor’s, master’s, and doctoral degrees from North Carolina State University, where he also served as a faculty member. He has been recognized by Harvard Business School as a Great American Business Leader.

John Crumpler is a General Partner at Hatteras Venture Partners, a firm he co-founded in 2000. He is responsible for the firm’s investments in healthcare and life science information technology, as well as overall fund operations. Prior to Hatteras, he was a successful technology entrepreneur, founding and leading E-Comm, Inc. until its acquisition. He holds an A.B. from Harvard University and serves on multiple healthcare boards.

Dr. Elder Granger oversees THE 5Ps, LLC as its President and CEO. He retired from the United States Army after more than 20 years of distinguished service as a medical officer. During his military career, he served as the Military Assistant and Senior Advisor to two Assistant Secretaries of Defense for Health Affairs. In this role, he helped manage the nation’s second-largest integrated health care system.

Dr. Norman Sharpless served as the director of the National Cancer Institute from 2017 to 2022 and acting commissioner of the FDA in 2019. He currently serves as Co-CEO of Jupiter BioVentures and is a Professor of Cancer Policy and Innovation at the University of North Carolina School of Medicine. Prior to his government service, Dr. Sharpless directed the UNC Lineberger Comprehensive Cancer Center. He is a recognized member of the National Academy of Medicine.

Dr. Danny Bar-Zohar is an Executive Board Member and the CEO of Healthcare at Merck KGaA. He joined Merck in 2020 as the Global Head of Development, bringing extensive R&D leadership experience from previous roles at Novartis and Teva Pharmaceuticals. Early in his career, he trained as a general surgeon in Israel and served as an airborne rescue physician in the Israel Defense Forces. He received his Doctor of Medicine from Tel Aviv University.

Dr. Peter WT Pisters is the President of The University of Texas MD Anderson Cancer Center. A renowned cancer surgeon and researcher, he previously served as President and CEO of the University Health Network in Toronto. Dr. Pisters earned his medical degree at the Schulich School of Medicine and Dentistry in Canada and completed postgraduate work at Memorial Sloan Kettering. He also holds a master’s degree in healthcare management from the Harvard T.H. Chan School of Public Health.

Dr. Sean Khozin is a physician-executive, board-certified oncologist, and data scientist. He currently serves as the Chief Executive Officer of the CEO Roundtable on Cancer and Project Data Sphere. Previously, he was the Global Head of Data Strategy at Johnson & Johnson and a founding member of the US FDA’s Oncology Center of Excellence. With over 15 years of experience, Dr. Khozin focuses on advancing innovations at the intersection of biology, technology, and artificial intelligence.

Dr. Imran Khan serves as Vice President of US Medical Affairs for Hematology at Johnson & Johnson Innovative Medicine, where he leads U.S. medical strategy. His career spans senior roles in global medical affairs and clinical development, including pivotal contributions to breakthrough therapies in multiple myeloma. He holds an MD and a PhD in Physiology and Biophysics. Dr. Khan also completed post-graduate training in internal medicine, hematology-oncology, and radiology.

Christopher A. Viehbacher is the President and CEO of Biogen and the Past Chairman of the CEO Roundtable on Cancer. He previously served as the CEO of Sanofi and Chairman of Genzyme, leading the company through a significant R&D transformation. After his tenure at Sanofi, he worked with Gurnet Point Capital, a healthcare venture capital fund. He is a certified public accountant and graduated from Queen’s University in Ontario, Canada.

Jean-Charles Soria is Amgen’s Senior Vice President of Oncology within Global Development. Prior to Amgen, he served as Director General of Institut Gustave Roussy, one of the world’s leading cancer centers, appointed by France’s Minister of Health and Solidarity. Dr. Soria is a medical oncologist and professor of medicine with deep expertise in thoracic oncology and early-phase drug development.

Dr. Kim Rathmell is CEO of The Ohio State University Comprehensive Cancer Center. A physician-scientist and national leader in cancer genomics, she has led major academic programs in translational oncology and precision medicine. Her appointment to the Life Sciences Council was announced in July 2025, reinforcing the Council’s integration of academic cancer center leadership alongside industry and government partners.

Dr. Sunil Verma oversees AstraZeneca’s global oncology franchise, spanning a broad portfolio across lung, breast, and hematologic cancers. A medical oncologist by training, he has held leadership roles in both clinical practice and industry R&D. His appointment to the Life Sciences Council was announced in July 2025.

Dr. Stu Bailey leads Clinical Measurement Sciences at EMD Serono, the biopharmaceutical business of Merck KGaA. His work spans clinical biomarker strategy, translational science, and data-driven approaches to drug development.

Dr. Marjorie Green leads late-stage oncology clinical development at Merck, where she oversees the advancement of the company’s oncology pipeline through pivotal trials and regulatory submissions.

Dr. Kiran Patel leads solid tumor clinical development and diagnostics strategy at Johnson & Johnson Innovative Medicine, driving the company’s oncology portfolio across multiple tumor types.